Instruction for use: Lavomax

Dosage form: Coated tablets

Active substance: Tiloronum

ATX

J05AX Other antivirals

Pharmacological groups

Antiviral immunostimulating agent - inducer of interferon formation [Antiviral (excluding HIV) means]

Antiviral immunostimulating agent - inducer of interferon formation [Interferon inductors]

The nosological classification (ICD-10)

A16.2 Tuberculosis of lungs without mention of bacteriological or histological confirmation: Disseminated tuberculosis; Caseous pneumonia; Pulmonary tuberculosis; Pulmonary tuberculosis; Tuberculosis of the lung chronic multidrug-resistant; Pulmonary tuberculosis; Fulminant tuberculosis of the lungs; Chronic tuberculosis of the lungs; Disseminated tuberculosis of the lungs

A56 Other chlamydial diseases, sexually transmitted infections: Chlamydial infections; Chlamydia; Tropical bubo

A56.2 Chlamydial infection of the urogenital tract, unspecified: Chlamydial urethritis; Urogenital chlamydia; Chlamydial gynecological infections; Cervicitis of chlamydial etiology

A56.4 Chlamydial pharyngitis: Respiratory chlamydia

B00 Infections caused by the herpes simplex virus [herpes simplex]: Herpes simplex; Herpes virus; Herpes simplex virus; Herpes simplex virus type I and II; HSV; Herpes; Herpes simplex / herpes simplex /; Herpes lips; Herpes simplex; Herpes in patients with immunodeficiency; Labial herpes; Acute herpetic disease of the mucous membranes; Herpes simplex; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Recurrent herpes; Urogenital herpetic infection; Chronic recurrent herpesvirus infection; Herpes-viral infections of various localizations

B15 Acute hepatitis A: Botkin's disease; Viral hepatitis A; Hepatitis A; Infectious hepatitis; Acute hepatitis; Acute viral hepatitis A; Subacute hepatitis; Lightning-fast hepatitis

B16 Acute hepatitis B: Viral hepatitis B; Hepatitis B; Acute hepatitis; Vaccination against hepatitis B; Subacute hepatitis; Acute viral hepatitis B; Acute lingering hepatitis B

B17.1 Acute hepatitis C: Viral active hepatitis C; Viral hepatitis C; Hepatitis C

B25 Cytomegalovirus: Generalized CMV infection in patients with AIDS; Cytomegalovirus infection in patients with impaired immunity; Cytomegalovirus infection; Cytomegalovirus infection in patients with habitual miscarriage Cytomegalovirus retinitis; Cytomegalovirus retinitis in AIDS patients; CMV; CMV in AIDS patients; CMV infection; CMV infection in the presence of immunodeficiency; CMV infection in cancer patients with immunosuppression; CMV-pneumonia; CMV retinitis in patients with weakened immunity; CMV retinitis in AIDS patients

G04 Encephalitis, myelitis and encephalomyelitis: Disseminated acute encephalomyelitis; Leukoencephalitis; Meningomielitis; Myelitis; Acute encephalitis; Acute encephalomyelitis; Chronic encephalitis; Chronic encephalomyelitis; Encephalitis; Encephalomyelitis; Inflammation of meninges

G05.1 Encephalitis, myelitis and encephalomyelitis in viral diseases classified elsewhere: Viral encephalomyelitis

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

J11 Influenza, virus not identified: Influenza; Influenza in the early stages of the disease; Influenza in children; cold in the chest; Begins flu-like condition; Acute disease parainfluenza; parainfluenza; parainfluenza state; influenza epidemics; The pains of the influenza

N34.1 Non-specific urethritis: Non-gonococcal urethritis; Chronic urethritis; Chronic urethrostrostitis; Urethritis of non-gonococcal (nonspecific)

Composition

Coated tablets.

active substance: Tilorone dihydrochloride 125 mg

Auxiliary substances: magnesium hydroxycarbonate (magnesium carbonate heavy) - 69 mg; Povidone K30 - 4 mg; Calcium stearate - 2 mg

Shell: sucrose - 158.11 mg; Povidone K17 - 5.65 mg; Copovidone - 0.44 mg; Magnesium hydroxycarbonate (magnesium carbonate light) - 25.7 mg; Titanium dioxide - 1.2 mg; Silicon dioxide colloid (aerosil A380) - 1 mg; Dye quinoline yellow 0.09 mg; The colorant "Sunset sunset" yellow - 0.01 mg; Macrogol 6000 - 6 mg; Beeswax - 0.15 mg; Paraffin liquid - 0.15 mg; Talc - 1.5 mg

Description of dosage form

Tablets: coated with a coating from yellow to orange color, round shape. The core of the tablet is orange.

Pharmachologic effect

Mode of action - antiviral, immunomodulating.

Pharmacodynamics

Tiloron stimulates the formation of α-, β-, γ- and λ-interferons in the body. The main producers of interferon in response to the introduction of tyloron are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration, the maximum production of interferon is determined in the intestine-liver-blood sequence after 4-24 hours. Tilorone has an immunomodulatory and antiviral effect. In human leukocytes, the synthesis of interferon is induced. Stimulates bone marrow stem cells, enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-help / T-suppressors. Effective against various viral infections, incl. Against influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with the inhibition of the transmission of virus-specific proteins in infected cells, as a result of which virus reproduction is suppressed.

Pharmacokinetics

After oral administration, Tylorone is rapidly absorbed from the digestive tract. Bioavailability is 60%. About 80% of Tyloron binds to plasma proteins. Tylorone is excreted almost unchanged through the intestine (70%) and the kidney (9%). T1 / 2 is 48 hours. Tylorone is not biotransformed and does not accumulate in the body.

Indications Lavomax

In adults:

Treatment and prevention of influenza and other ARVI;

In the complex therapy of herpetic infection, CMV infection;

In the complex therapy of urogenital and respiratory chlamydia, in the complex therapy of non-gonococcal urethritis;

In the complex therapy of viral hepatitis A, B, C;

In the complex therapy of pulmonary tuberculosis;

In the complex therapy of infectious-allergic and viral encephalomyelitis.

Contraindications

Hypersensitivity to the drug;

Sugarase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption (the preparation contains sucrose);

Period of pregnancy and lactation;

Children's age till 18 years.

Side effects

Possible allergic reactions, dyspeptic phenomena, short-term chills.

Interaction

Compatible with antibiotics and traditional treatment of viral and bacterial diseases.

Clinically significant interaction of Lavomax ® with antibiotics, standard means of treatment of viral and bacterial diseases, alcohol is not revealed.

Dosing and Administration

Inside, after a meal.

In the treatment of influenza and other acute respiratory viral infections: in the first two days of the disease, 125 mg, then 48 hours after 125 mg. The course dose is 750 mg (for the course of treatment 6 tablets for 125 mg).

For the prevention of influenza and other SARS: 125 mg once a week for 6 weeks (for treatment - 6 tablets for 125 mg).

For the treatment of herpetic, CMV infection: the first two days of 125 mg, then 48 hours at 125 mg. The course dose is 1.25-2.5 g (for the course of treatment - 10-20 tablets for 125 mg).

With urogenital and respiratory chlamydia, non-gonococcal urethritis: the first two days of 125 mg, then 48 hours after 125 mg. The course dose is 1.25 g (for the course of treatment - 10 tables for 125 mg).

For the treatment of viral hepatitis A: the first day of 125 mg 2 times, then 125 mg after 48 hours. The course dose is 1.25 g (for the course of treatment - 10 tables of 125 mg).

For the treatment of acute hepatitis B: the first and second days of 125 mg, then 125 mg after 48 hours. The course dose is 2 g (for the course of treatment - 16 tables of 125 mg), with prolonged course of hepatitis B - 125 mg 2 times Per day on the first day, then 125 mg after 48 hours. The course dose is 2.5 g (for the course of treatment, 20 tablets for 125 mg).

In chronic hepatitis B: the initial phase of treatment (2.5 g) - the first 2 days for 125 mg 2 times a day, then 125 mg after 48 hours. The continuation phase (from 1.25 g to 2.5 g) 125 mg / week. The course dose of Lavomax ® is from 3.75 to 5 g (for treatment course - from 30 to 40 tablets of 125 mg), the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies reflecting Degree of activity of the process.

In acute hepatitis C: the first and second days of 125 mg, then 125 mg after 48 hours. The course dose is 2.5 g (for treatment - 20 tablets for 125 mg).

In chronic hepatitis C: the initial phase of treatment (2.5 g) - the first two days of 125 mg twice a day, then 125 mg after 48 hours. The continuation phase (2.5 g) - 125 mg / week. The course dose of Lavomax ® is 5 g (for the course of treatment - 40 tablets for 125 mg), the duration of therapy is 6 months, depending on the results of biochemical, immunological, and morphological markers of the activity of the process.

As part of a comprehensive therapy for pulmonary tuberculosis: the first two days of 250 mg, then 125 mg after 48 hours. The course dose is 2.5 g (for the course of treatment - 20 tables of 125 mg).

In the complex therapy of infectious-allergic and viral encephalomyelitis: 125-250 mg / day for the first 2 days of treatment, then 125 mg after 48 hours. The dose is set individually, the course of treatment is 3-4 weeks.

Overdose

Cases of overdose are unknown.

Special instructions

Impact on the ability to drive vehicles and work with mechanisms. The use of the drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Release form

Tablets coated with a coating, 125 mg. By 3, 4, 6 or 10 tab. In a planar cell package. 1 or 2 contour squares are placed in a cardboard pack.

Manufacturer

Producer / organization accepting claims:

JSC "Nizhpharm", Russia

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Lavomax

In a dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

The shelf life of the drug Lavomax

2 years.

Do not use beyond the expiration date printed on the package.